$0.9639
At close: Apr 16 EDT
$0.9850
0.022.19%
Pre-Market: 7:55 PM EDT
Comments
Loading...
Esperion Therapeutics Analyst Ratings and Price Targets | NASDAQ:ESPR | Benzinga
Esperion Therapeutics Inc has a consensus price target of $5.94 based on the ratings of 10 analysts. The high is $16 issued by HC Wainwright & Co. on March 20, 2025. The low is $2.5 issued by B of A Securities on June 20, 2024. The 3 most-recent analyst ratings were released by Needham, HC Wainwright & Co., and Citizens Capital Markets on April 8, 2025, March 20, 2025, and March 5, 2025, respectively. With an average price target of $8.33 between Needham, HC Wainwright & Co., and Citizens Capital Markets, there's an implied 746.02% upside for Esperion Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
HC Wainwright & Co.
Citizens Capital Markets
JMP Securities
Goldman Sachs
1calculated from analyst ratings
Analyst Ratings for Esperion Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/08/2025 | Buy Now | 407.61% | Needham | Serge Belanger64% | $5 → $5 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2025 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/05/2025 | Buy Now | 306.09% | Citizens Capital Markets | Jason Butler51% | $4 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 03/04/2025 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 02/11/2025 | Buy Now | 306.09% | JMP Securities | Roy Buchanan34% | $7 → $4 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 02/11/2025 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/23/2025 | Buy Now | 610.66% | JMP Securities | Roy Buchanan34% | $7 → $7 | Reiterates | Market Outperform → Market Outperform | Get Alert |
| 01/23/2025 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 01/10/2025 | Buy Now | — | HC Wainwright & Co. | Joseph Pantginis43% | — | Reiterates | Buy → Buy | Get Alert |
| 12/18/2024 | Buy Now | 306.09% | Goldman Sachs | Paul Choi59% | → $4 | Reinstates | → Neutral | Get Alert |
| 12/17/2024 | Buy Now | 712.18% | Cantor Fitzgerald | Kristen Kluska65% | → $8 | Initiates | → Overweight | Get Alert |
| 12/13/2024 | Buy Now | 509.14% | Needham | Serge Belanger64% | $6 → $6 | Reiterates | Buy → Buy | Get Alert |
| 12/13/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/12/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 12/03/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Maintains | Buy | Get Alert |
| 12/02/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/27/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/19/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 10/02/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 08/13/2024 | Buy Now | 509.14% | Needham | Serge Belanger64% | $8 → $6 | Maintains | Buy | Get Alert |
| 08/12/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 712.18% | Needham | Serge Belanger64% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 06/28/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | 153.81% | B of A Securities | Jason Zemansky72% | $2.9 → $2.5 | Downgrade | Neutral → Underperform | Get Alert |
| 05/22/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/21/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/08/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 05/07/2024 | Buy Now | 712.18% | Needham | Serge Belanger64% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 04/10/2024 | Buy Now | 712.18% | Needham | Serge Belanger64% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $16 → $16 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 712.18% | Needham | Serge Belanger64% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 02/28/2024 | Buy Now | 1524.37% | HC Wainwright & Co. | Joseph Pantginis43% | $22 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | 712.18% | Needham | Serge Belanger64% | $8 → $8 | Reiterates | Buy → Buy | Get Alert |
| 01/03/2024 | Buy Now | 153.81% | B of A Securities | Jason Zemansky72% | $4 → $2.5 | Downgrade | Buy → Neutral | Get Alert |
| 11/20/2023 | Buy Now | — | JP Morgan | Jessica Fye63% | — | Reinstates | → Neutral | Get Alert |
| 11/13/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 11/07/2023 | Buy Now | 712.18% | Needham | Serge Belanger64% | $9 → $8 | Maintains | Buy | Get Alert |
| 10/02/2023 | Buy Now | 813.71% | Needham | Serge Belanger64% | → $9 | Reiterates | Buy → Buy | Get Alert |
| 08/28/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 08/02/2023 | Buy Now | 813.71% | Needham | Serge Belanger64% | $10 → $9 | Maintains | Buy | Get Alert |
| 06/26/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | Buy → Buy | Get Alert |
| 06/15/2023 | Buy Now | 306.09% | B of A Securities | Jason Zemansky72% | $1.25 → $4 | Upgrade | Underperform → Buy | Get Alert |
| 06/01/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | → Buy | Get Alert |
| 05/09/2023 | Buy Now | 915.23% | Needham | Serge Belanger64% | $12 → $10 | Maintains | Buy | Get Alert |
| 04/18/2023 | Buy Now | 1118.27% | Needham | Serge Belanger64% | → $12 | Reiterates | → Buy | Get Alert |
| 03/28/2023 | Buy Now | 1118.27% | Needham | Serge Belanger64% | → $12 | Reiterates | → Buy | Get Alert |
| 03/20/2023 | Buy Now | 204.57% | Morgan Stanley | Jeffrey Hung50% | $9 → $3 | Maintains | Equal-Weight | Get Alert |
| 03/16/2023 | Buy Now | 52.28% | B of A Securities | Jason Zemansky72% | $8 → $1.5 | Downgrade | Neutral → Underperform | Get Alert |
| 03/16/2023 | Buy Now | 1118.27% | Needham | Serge Belanger64% | $16 → $12 | Maintains | Buy | Get Alert |
| 03/16/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | → Buy | Get Alert |
| 03/07/2023 | Buy Now | 610.66% | Credit Suisse | Judah Frommer66% | $6.5 → $7 | Upgrade | Underperform → Neutral | Get Alert |
| 03/06/2023 | Buy Now | 1422.84% | JMP Securities | Roy Buchanan34% | → $15 | Reiterates | → Market Outperform | Get Alert |
| 03/06/2023 | Buy Now | 1524.37% | Needham | Serge Belanger64% | $12 → $16 | Maintains | Buy | Get Alert |
| 03/06/2023 | Buy Now | 2133.5% | HC Wainwright & Co. | Joseph Pantginis43% | → $22 | Reiterates | → Buy | Get Alert |
| 02/27/2023 | Buy Now | 813.71% | JP Morgan | Jessica Fye63% | $8 → $9 | Maintains | Neutral | Get Alert |
| 02/27/2023 | Buy Now | 712.18% | B of A Securities | Jason Zemansky72% | → $8 | Reinstates | → Neutral | Get Alert |
| 02/22/2023 | Buy Now | 1118.27% | Needham | Serge Belanger64% | → $12 | Reiterates | → Buy | Get Alert |
| 02/03/2023 | Buy Now | 813.71% | Morgan Stanley | Jeffrey Hung50% | → $9 | Upgrade | Underweight → Equal-Weight | Get Alert |
| 11/02/2022 | Buy Now | 813.71% | Morgan Stanley | Jeffrey Hung50% | $7 → $9 | Maintains | Underweight | Get Alert |
| 08/03/2022 | Buy Now | 509.14% | Credit Suisse | Judah Frommer66% | $7 → $6 | Downgrade | Neutral → Underperform | Get Alert |
| 07/15/2022 | Buy Now | 610.66% | Morgan Stanley | Jeffrey Hung50% | $5 → $7 | Maintains | Underweight | Get Alert |
| 05/24/2022 | Buy Now | 204.57% | Goldman Sachs | Paul Choi59% | $3.5 → $3 | Maintains | Sell | Get Alert |
| 05/05/2022 | Buy Now | — | JP Morgan | Jessica Fye63% | — | Upgrade | Underweight → Neutral | Get Alert |
FAQ
What is the target price for Esperion Therapeutics (ESPR) stock?
The latest price target for Esperion Therapeutics (NASDAQ:ESPR) was reported by Needham on April 8, 2025. The analyst firm set a price target for $5.00 expecting ESPR to rise to within 12 months (a possible 407.61% upside). 29 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Esperion Therapeutics (ESPR)?
The latest analyst rating for Esperion Therapeutics (NASDAQ:ESPR) was provided by Needham, and Esperion Therapeutics reiterated their buy rating.
When was the last upgrade for Esperion Therapeutics (ESPR)?
The last upgrade for Esperion Therapeutics Inc happened on June 15, 2023 when B of A Securities raised their price target to $4. B of A Securities previously had an underperform for Esperion Therapeutics Inc.
When was the last downgrade for Esperion Therapeutics (ESPR)?
The last downgrade for Esperion Therapeutics Inc happened on June 20, 2024 when B of A Securities changed their price target from $2.9 to $2.5 for Esperion Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Esperion Therapeutics (ESPR)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Esperion Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Esperion Therapeutics was filed on April 8, 2025 so you should expect the next rating to be made available sometime around April 8, 2026.
Is the Analyst Rating Esperion Therapeutics (ESPR) correct?
While ratings are subjective and will change, the latest Esperion Therapeutics (ESPR) rating was a reiterated with a price target of $5.00 to $5.00. The current price Esperion Therapeutics (ESPR) is trading at is $0.99, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
